Correlation Between Protagenic Therapeutics and Defence Therapeutics

Can any of the company-specific risk be diversified away by investing in both Protagenic Therapeutics and Defence Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protagenic Therapeutics and Defence Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Protagenic Therapeutics and Defence Therapeutics, you can compare the effects of market volatilities on Protagenic Therapeutics and Defence Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protagenic Therapeutics with a short position of Defence Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protagenic Therapeutics and Defence Therapeutics.

Diversification Opportunities for Protagenic Therapeutics and Defence Therapeutics

-0.87

Correlation Coefficient

Protagenic Therapeutics  Defence Therapeutics

Pay attention - limited upside

The 3 months correlation between Protagenic and Defence is -0.87. Overlapping area represents the amount of risk that can be diversified away by holding Protagenic Therapeutics and Defence Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Defence Therapeutics and Protagenic Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protagenic Therapeutics are associated (or correlated) with Defence Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Defence Therapeutics has no effect on the direction of Protagenic Therapeutics i.e., Protagenic Therapeutics and Defence Therapeutics go up and down completely randomly.

Pair Corralation between Protagenic Therapeutics and Defence Therapeutics

Given the investment horizon of 90 days Protagenic Therapeutics is expected to under-perform the Defence Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Protagenic Therapeutics is 1.01 times less risky than Defence Therapeutics. The stock trades about -0.11 of its potential returns per unit of risk. The Defence Therapeutics is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest  39.00  in Defence Therapeutics on December 30, 2024 and sell it today you would earn a total of  61.00  from holding Defence Therapeutics or generate 156.41% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	96.88%
Values	Daily Returns

Protagenic Therapeutics  vs.  Defence Therapeutics

Protagenic Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Protagenic Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Defence Therapeutics

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Defence Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak technical and fundamental indicators, Defence Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Protagenic Therapeutics and Defence Therapeutics

The main advantage of trading using opposite Protagenic Therapeutics and Defence Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protagenic Therapeutics position performs unexpectedly, Defence Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Defence Therapeutics will offset losses from the drop in Defence Therapeutics' long position.

The idea behind Protagenic Therapeutics and Defence Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.